Bronstein, Gewirtz & Grossman, LLC Investigates Potential Claims Against Paragon 28, Inc.
On April 3, 2025, Bronstein, Gewirtz & Grossman, LLC, a leading national securities fraud law firm, announced that it is investigating potential claims on behalf of purchasers of Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSE:FNA). The investigation concerns whether Paragon 28 and certain of its officers or directors have violated the federal securities laws.
Background on Paragon 28
Paragon 28 is a medical technology company dedicated to advancing surgical innovation for the orthopedic community. The Company’s portfolio includes innovative product offerings in the extremities and spine markets.
The Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating whether Paragon 28 and its executives violated the securities laws by making false and/or misleading statements and/or failing to disclose material information to investors. Specifically, the investigation focuses on whether the Company misrepresented the commercial prospects of its products, particularly in the spine market.
Impact on Individual Investors
If you purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, you may be eligible to participate in the investigation. The investigation aims to determine whether the Company and its executives violated securities laws and may have caused investors to suffer significant losses.
Potential Impact on the World
The impact of this investigation on the world at large could be significant. Paragon 28’s innovative products have the potential to revolutionize orthopedic surgery, particularly in the areas of extremities and spine. However, if it is discovered that the Company misrepresented the commercial prospects of these products, it could lead to a loss of confidence in the Company and the medical technology sector as a whole.
Conclusion
Bronstein, Gewirtz & Grossman, LLC’s investigation into Paragon 28 is an important development for investors in the medical technology sector. The potential for securities fraud can have far-reaching consequences, both for individual investors and the broader market. If you purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, we encourage you to visit bgandg.com/FNA to learn more about the investigation and how you may be able to assist.
Additional Information
Based on other online sources, the investigation into Paragon 28 could result in various outcomes. These may include regulatory action against the Company, settlements with investors, or even litigation. The exact impact on Paragon 28 and its investors will depend on the findings of the investigation.
- Regulatory action: The Securities and Exchange Commission (SEC) or other regulatory bodies could investigate Paragon 28 and take enforcement action if they find evidence of securities fraud.
- Settlements: The Company could choose to settle with investors, potentially offering compensation for any losses suffered as a result of the alleged securities fraud.
- Litigation: If the investigation leads to litigation, the outcome will depend on the merits of the case and the applicable laws.
Regardless of the outcome, this investigation serves as a reminder of the importance of transparency and truthfulness in the securities markets. It also highlights the role that investors can play in holding companies accountable for their actions.
If you have any questions or would like more information, please contact Bronstein, Gewirtz & Grossman, LLC at (212) 697-6484 or [email protected].
This press release is for informational purposes only and is not a call to action or solicitation for business.
